To the full analysis
Ingevity stock: growth
NGVTIngevity reported $1.17B in revenue for fiscal 2025, down 17% on the prior year, up 6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
1.7%
per year from 2012 to 2025, per share 2.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
9.3%
per year from 2012 to 2025, per share 10.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | −0.8% | 1.9% | 1.7% |
| Revenue per share | 1.8% | 3.4% | 2.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 2.1% | no data | 9.3% |
| Free cash flow per share | 4.8% | no data | 10.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $939M | $119M | $86M |
| 2013 | $980M | $119M | $74M |
| 2014 | $1.04B | $129M | $42M |
| 2015 | $968M | $80M | −$29M |
| 2016 | $908.3M | $35.2M | $71.2M |
| 2017 | $972.4M | $126.3M | $121.7M |
| 2018 | $1.13B | $169.1M | $158.1M |
| 2019 | $1.29B | $183.7M | $160.9M |
| 2020 | $1.22B | $181.4M | $246.5M |
| 2021 | $1.39B | $118.1M | $189.5M |
| 2022 | $1.67B | $211.6M | $170.9M |
| 2023 | $1.69B | −$5.4M | $95.3M |
| 2024 | $1.41B | −$430.3M | $51M |
| 2025 | $1.17B | −$167.1M | $273.5M |
Revenue by segment
How Ingevity Corporation makes its money and how that has shifted. Names are as the company reports them.
- Performance Materials52%
- Performance Chemicals34%
- Other14%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Performance Materials | $400.4M | $490.6M | $510M | $516.8M | $548.5M | $586M | $609.6M | $606.9M | 52% |
| Performance Chemicals | $733.2M | $802.3M | $706.1M | $874.7M | $1.12B | $902.1M | $608.2M | $400.5M | 34.3% |
| Other | $0 | $0 | $0 | $0 | $0 | $204M | $188.6M | $160.2M | 13.7% |
| Total revenue | $1.13B | $1.29B | $1.22B | $1.39B | $1.67B | $1.69B | $1.41B | $1.17B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.